Not losing weight on 5mg Mounjaro: what's actually going on

You're four weeks in at 5mg and nothing is moving. Sound familiar?

Picture it: you've just collected your second 5mg pen. The nausea that hit you on 2.5mg has mostly settled, your appetite is noticeably quieter, but when you step on the scales, you're looking at virtually the same number as last month. It's a frustrating spot to be in, especially when you expected this dose increase to accelerate things.

Here's the practical truth. Tirzepatide works by activating two gut-hormone receptors (GIP and GLP-1) that regulate appetite and how your body processes energy. When you step up a dose, your system takes time to recalibrate. Adipose tissue doesn't release stored fat on a neat weekly schedule; hormonal and metabolic adjustments can take four to six weeks to show up on the scales. A plateau at 5mg, particularly in the first two to four weeks of that pen, is not a sign the medicine has stopped working. The NHS medicines page for tirzepatide notes that it takes time for the full effect to develop.

One checking habit worth building: note your weight at the same time of day, once a week, after using the toilet and before eating. A single morning's reading can be misleading by up to 2kg depending on hydration and what you ate the day before. Weekly averages tell a far more honest story than daily fluctuations. That alone (done in under a minute each week) removes a lot of false alarms.

If you've read through the general Mounjaro overview on the Mounjaro treatment page and still have questions about why this particular dose feels different, read on.

The metabolic adaptation problem, and why 5mg sits in the middle of it

When calorie intake drops, the body responds by lowering its resting metabolic rate. This is not a malfunction; it's a survival mechanism that evolved over millennia. Tirzepatide blunts appetite strongly, but it cannot fully override this compensatory slow-down. The result is that weight loss at any given dose can decelerate even when you're eating meaningfully less than before.

At 5mg, you're also sitting in the middle of the licensed dose range. NICE's appraisal of tirzepatide, TA1026, notes that the largest average weight reductions in SURMOUNT-1 were observed at higher doses, up to around 20–21% average body-weight reduction at 15mg over 72 weeks. Some people do achieve strong results at 5mg, but the clinical data consistently shows dose-related response: higher doses, on average, produce greater loss. This is exactly why titration exists, and why a prescriber reviews your progress before recommending you move up.

Protein intake is worth a specific mention. With appetite suppressed, it's easy to eat less overall but inadvertently let protein slip too. Muscle loss under calorie restriction slows metabolism further, and can make the plateau feel permanent when it isn't. If you haven't already looked at what to expect at the 5mg dose stage, that page covers the dietary habits that tend to support better results at this point in treatment.

When to take it seriously and speak to your prescriber

A short plateau is expected. A longer one (say, six or more weeks at 5mg with no measurable change and no obvious explanation) is a different conversation. There are a handful of reasons this can happen that have nothing to do with effort or willpower.

Thyroid function is one. Subclinical hypothyroidism can suppress weight loss even when everything else looks right, and it often goes undetected. Medications that promote weight gain (certain antidepressants, steroids, beta-blockers) interact with tirzepatide's effectiveness without cancelling it outright. Sleep quality matters more than most people realise; poor sleep elevates ghrelin and cortisol in ways that actively resist fat loss.

If you're also on the 2.5mg dose and haven't seen movement there either, the considerations on not losing weight at 2.5mg overlap with what applies here. Conversely, if you're already wondering whether 7.5mg might be the right next step, the prescriber conversation around that transition is covered on the 7.5mg plateau page.

The key point: don't adjust your dose yourself, skip a dose to compensate, or switch medicines without clinical input. These are decisions a prescriber makes with your full health history in view, not ones to make based on a forum post. If you'd like that conversation, our prescribers are available through a free consultation.

What the evidence says about persistence, and one cost consideration

The SURMOUNT-1 trial involved 2,539 adults and ran for 72 weeks. Participants who stayed on treatment and continued titrating saw sustained, meaningful losses. If you are finding the scales stubbornly unmoved right now, our dedicated guide to why weight loss can stall specifically at the 5mg stage works through the most common causes and what you can do about them. Persistence through the titration phase, with prescriber support, is what the clinical data supports.

One thing people raise at this stage is whether it's worth continuing if progress has stalled. That's a fair question. If you're curious about the cost side of ongoing treatment and what a private prescription actually covers, the Mounjaro price comparison page lays out what different providers include, and what they don't. Understanding the full picture of what you're paying for, including aftercare and prescriber access, matters especially when you're at a point where clinical support is most needed.

Questions about whether your specific situation warrants a dose change, a pause, or further investigation are exactly what a prescriber consultation is for. A clinician review at this point isn't starting from scratch, it's the check-in the treatment plan was always meant to include.